Literature DB >> 10206324

Serum protein binding of tolterodine and its major metabolites in humans and several animal species.

I Påhlman1, P Gozzi.   

Abstract

The aim of this study was to determine in vitro protein binding of tolterodine and its 5-hydroxymethyl (5-HM) and N-dealkylated metabolites in serum from humans and several animal species at concentrations similar to those obtained in clinical and preclinical studies. Binding of tolterodine and the two metabolites to human serum albumin and alpha1-acid glycoprotein (AAG) was also assessed, as was binding of tolterodine to red blood cells. Ex vivo protein binding of tolterodine and 5-HM was determined in serum samples from healthy volunteers treated with oral tolterodine 4 mg twice daily for 8 days. Tolterodine exhibited high protein binding in human serum; the unbound fraction (f(u)) was 3.7%. The unbound fraction of tolterodine in cat and dog serum (1.5 and 2.1%, respectively) was lower compared with human serum; f(u) was higher in the other species investigated (rat, 22%; mouse, 16-17%; rabbit, 39%). The unbound fraction of 5-HM was much higher in serum from humans (36%) and all animal species investigated (mouse, 72%; rabbit, 68%; cat, 32%; dog, 45%). Binding of N-dealkylated tolterodine to proteins in human serum was intermediate (f(u) 14%). AAG was the major binding protein for tolterodine and 5-HM, and the degree of binding increased with increasing concentration of the protein. The association constant of 5-HM for AAG was lower than that of tolterodine (1.3 x 10(5) M(-1) versus 2.1 x 10(6) M(-1)). The blood:plasma tolterodine concentration ratio was 0.6 in both humans and dog; thus, a minor fraction of tolterodine was present in red blood cells compared with plasma (0.18 and 0.36, respectively). In the mouse, tolterodine was equally present in blood and plasma. In ex vivo samples, f(u) values for tolterodine (pH adjusted) varied between 1.6 and 4.9% (mean 2.8%), which could be explained by differences in AAG concentrations. There was good correlation between observed f(u) values for tolterodine and those predicted on the basis of AAG levels. Similar findings were observed for 5-HM.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10206324     DOI: 10.1002/(sici)1099-081x(199903)20:2<91::aid-bdd162>3.0.co;2-y

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  15 in total

1.  Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.

Authors:  B Olsson; J Szamosi
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.

Authors:  N Brynne; C Svanström; A Aberg-Wistedt; B Hallén; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

3.  Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.

Authors:  N Brynne; C Forslund; B Hallén; L L Gustafsson; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

4.  Cytochrome P450 Enzyme Metabolites in Lead Discovery and Development.

Authors:  Sylvie E Kandel; Larry C Wienkers; Jed N Lampe
Journal:  Annu Rep Med Chem       Date:  2014       Impact factor: 1.059

5.  Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin.

Authors:  Gayatri Sathyan; Roger R Dmochowski; Rodney A Appell; Cindy Guo; Suneel K Gupta
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 6.  Tolterodine: a review of its use in the treatment of overactive bladder.

Authors:  D Clemett; B Jarvis
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 7.  Studies of metabolite-protein interactions: a review.

Authors:  Ryan Matsuda; Cong Bi; Jeanethe Anguizola; Matthew Sobansky; Elliott Rodriguez; John Vargas Badilla; Xiwei Zheng; Benjamin Hage; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-11-25       Impact factor: 3.205

8.  In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.

Authors:  Shuji Maruyama; Naoki Hasuike; Kazuhiro Suzuki; Shizuo Yamada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-12       Impact factor: 3.000

9.  Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.

Authors:  Aneta Doricakova; Dirk Theile; Johanna Weiss; Radim Vrzal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-27       Impact factor: 3.000

Review 10.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.